Targeting myocardial substrate metabolism in heart failure

Potential for new therapies

Hossein Ardehali, Hani N. Sabbah, Michael A. Burke, Satyam Sarma, Peter P. Liu, John G.F. Cleland, Aldo Maggioni, Gregg C. Fonarow, E. Dale Abel, Umberto Campia, Mihai Gheorghiade

Research output: Contribution to journalReview article

95 Citations (Scopus)

Abstract

The incidence and prevalence of heart failure have increased significantly over the past few decades. Available data suggest that patients with heart failure independent of the aetiology have viable but dysfunctional myocardium that is potentially salvageable. Although a great deal of research effort has focused on characterizing the molecular basis of heart failure, cardiac metabolism in this disorder remains an understudied discipline. It is known that many aspects of cardiomyocyte energetics are altered in heart failure. These include a shift from fatty acid to glucose as a preferred substrate and a decline in the levels of ATP. Despite these demonstrated changes, there are currently no approved drugs that target metabolic enzymes or proteins in heart failure. This is partly due to our limited knowledge of the mechanisms and pathways that regulate cardiac metabolism. Better characterization of these pathways may potentially lead to new therapies for heart failure. Targeting myocardial energetics in the viable and potentially salvageable tissue may be particularly effective in the treatment of heart failure. Here, we will review metabolic changes that occur in fatty acid and glucose metabolism and AMP-activated kinase in heart failure. We propose that cardiac energetics should be considered as a potential target for therapy in heart failure and more research should be done in this area.

Original languageEnglish (US)
Pages (from-to)120-129
Number of pages10
JournalEuropean Journal of Heart Failure
Volume14
Issue number2
DOIs
StatePublished - Feb 1 2012

Fingerprint

Heart Failure
Therapeutics
Fatty Acids
Glucose
AMP-Activated Protein Kinases
Treatment Failure
Research
Cardiac Myocytes
Myocardium
Adenosine Triphosphate
Incidence
Enzymes
Pharmaceutical Preparations
Proteins

Keywords

  • AMP-activated kinase
  • Cardiac metabolism
  • Energetics
  • Heart failure

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Ardehali, H., Sabbah, H. N., Burke, M. A., Sarma, S., Liu, P. P., Cleland, J. G. F., ... Gheorghiade, M. (2012). Targeting myocardial substrate metabolism in heart failure: Potential for new therapies. European Journal of Heart Failure, 14(2), 120-129. https://doi.org/10.1093/eurjhf/hfr173

Targeting myocardial substrate metabolism in heart failure : Potential for new therapies. / Ardehali, Hossein; Sabbah, Hani N.; Burke, Michael A.; Sarma, Satyam; Liu, Peter P.; Cleland, John G.F.; Maggioni, Aldo; Fonarow, Gregg C.; Abel, E. Dale; Campia, Umberto; Gheorghiade, Mihai.

In: European Journal of Heart Failure, Vol. 14, No. 2, 01.02.2012, p. 120-129.

Research output: Contribution to journalReview article

Ardehali, H, Sabbah, HN, Burke, MA, Sarma, S, Liu, PP, Cleland, JGF, Maggioni, A, Fonarow, GC, Abel, ED, Campia, U & Gheorghiade, M 2012, 'Targeting myocardial substrate metabolism in heart failure: Potential for new therapies', European Journal of Heart Failure, vol. 14, no. 2, pp. 120-129. https://doi.org/10.1093/eurjhf/hfr173
Ardehali, Hossein ; Sabbah, Hani N. ; Burke, Michael A. ; Sarma, Satyam ; Liu, Peter P. ; Cleland, John G.F. ; Maggioni, Aldo ; Fonarow, Gregg C. ; Abel, E. Dale ; Campia, Umberto ; Gheorghiade, Mihai. / Targeting myocardial substrate metabolism in heart failure : Potential for new therapies. In: European Journal of Heart Failure. 2012 ; Vol. 14, No. 2. pp. 120-129.
@article{174c438e88d9436c814dbe18b6a57b57,
title = "Targeting myocardial substrate metabolism in heart failure: Potential for new therapies",
abstract = "The incidence and prevalence of heart failure have increased significantly over the past few decades. Available data suggest that patients with heart failure independent of the aetiology have viable but dysfunctional myocardium that is potentially salvageable. Although a great deal of research effort has focused on characterizing the molecular basis of heart failure, cardiac metabolism in this disorder remains an understudied discipline. It is known that many aspects of cardiomyocyte energetics are altered in heart failure. These include a shift from fatty acid to glucose as a preferred substrate and a decline in the levels of ATP. Despite these demonstrated changes, there are currently no approved drugs that target metabolic enzymes or proteins in heart failure. This is partly due to our limited knowledge of the mechanisms and pathways that regulate cardiac metabolism. Better characterization of these pathways may potentially lead to new therapies for heart failure. Targeting myocardial energetics in the viable and potentially salvageable tissue may be particularly effective in the treatment of heart failure. Here, we will review metabolic changes that occur in fatty acid and glucose metabolism and AMP-activated kinase in heart failure. We propose that cardiac energetics should be considered as a potential target for therapy in heart failure and more research should be done in this area.",
keywords = "AMP-activated kinase, Cardiac metabolism, Energetics, Heart failure",
author = "Hossein Ardehali and Sabbah, {Hani N.} and Burke, {Michael A.} and Satyam Sarma and Liu, {Peter P.} and Cleland, {John G.F.} and Aldo Maggioni and Fonarow, {Gregg C.} and Abel, {E. Dale} and Umberto Campia and Mihai Gheorghiade",
year = "2012",
month = "2",
day = "1",
doi = "10.1093/eurjhf/hfr173",
language = "English (US)",
volume = "14",
pages = "120--129",
journal = "European Journal of Heart Failure",
issn = "1388-9842",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Targeting myocardial substrate metabolism in heart failure

T2 - Potential for new therapies

AU - Ardehali, Hossein

AU - Sabbah, Hani N.

AU - Burke, Michael A.

AU - Sarma, Satyam

AU - Liu, Peter P.

AU - Cleland, John G.F.

AU - Maggioni, Aldo

AU - Fonarow, Gregg C.

AU - Abel, E. Dale

AU - Campia, Umberto

AU - Gheorghiade, Mihai

PY - 2012/2/1

Y1 - 2012/2/1

N2 - The incidence and prevalence of heart failure have increased significantly over the past few decades. Available data suggest that patients with heart failure independent of the aetiology have viable but dysfunctional myocardium that is potentially salvageable. Although a great deal of research effort has focused on characterizing the molecular basis of heart failure, cardiac metabolism in this disorder remains an understudied discipline. It is known that many aspects of cardiomyocyte energetics are altered in heart failure. These include a shift from fatty acid to glucose as a preferred substrate and a decline in the levels of ATP. Despite these demonstrated changes, there are currently no approved drugs that target metabolic enzymes or proteins in heart failure. This is partly due to our limited knowledge of the mechanisms and pathways that regulate cardiac metabolism. Better characterization of these pathways may potentially lead to new therapies for heart failure. Targeting myocardial energetics in the viable and potentially salvageable tissue may be particularly effective in the treatment of heart failure. Here, we will review metabolic changes that occur in fatty acid and glucose metabolism and AMP-activated kinase in heart failure. We propose that cardiac energetics should be considered as a potential target for therapy in heart failure and more research should be done in this area.

AB - The incidence and prevalence of heart failure have increased significantly over the past few decades. Available data suggest that patients with heart failure independent of the aetiology have viable but dysfunctional myocardium that is potentially salvageable. Although a great deal of research effort has focused on characterizing the molecular basis of heart failure, cardiac metabolism in this disorder remains an understudied discipline. It is known that many aspects of cardiomyocyte energetics are altered in heart failure. These include a shift from fatty acid to glucose as a preferred substrate and a decline in the levels of ATP. Despite these demonstrated changes, there are currently no approved drugs that target metabolic enzymes or proteins in heart failure. This is partly due to our limited knowledge of the mechanisms and pathways that regulate cardiac metabolism. Better characterization of these pathways may potentially lead to new therapies for heart failure. Targeting myocardial energetics in the viable and potentially salvageable tissue may be particularly effective in the treatment of heart failure. Here, we will review metabolic changes that occur in fatty acid and glucose metabolism and AMP-activated kinase in heart failure. We propose that cardiac energetics should be considered as a potential target for therapy in heart failure and more research should be done in this area.

KW - AMP-activated kinase

KW - Cardiac metabolism

KW - Energetics

KW - Heart failure

UR - http://www.scopus.com/inward/record.url?scp=84856134386&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856134386&partnerID=8YFLogxK

U2 - 10.1093/eurjhf/hfr173

DO - 10.1093/eurjhf/hfr173

M3 - Review article

VL - 14

SP - 120

EP - 129

JO - European Journal of Heart Failure

JF - European Journal of Heart Failure

SN - 1388-9842

IS - 2

ER -